Transapical aortic valve implantation with the Corevalve Revalving System was successfully performed, demonstrating feasibility for high-risk patients with inadequate groin access.
Case Report (n=1)
No
Is transapical aortic valve implantation with the CoreValve ReValving system feasible in a high-risk patient without adequate transfemoral access?
This case report demonstrates the first successful transapical delivery of the CoreValve system, expanding TAVR access to patients with severe peripheral vascular disease.
On June 26, 2007, the Clinic for Cardiovascular Surgery at the German Heart Center Technical University in Munich successfully implanted a bioprosthetic valve via the apex of the heart within the framework of the CoreValve TAVR ReValving (Corevalve Inc., Irvine, CA, USA) clinical trial. The self-expanding aortic valve prosthesis is primarily designed for retrograde delivery across the aortic valve. The described transapical approach, however, now allows for treatment in those patients who have, for instance, no adequate "access" in the groin vessels due to peripheral vascular disease. Therefore, its feasibility must be considered as a major step in treating high-risk patients.
Lange et al. (Thu,) conducted a case report in Aortic valve disease with inadequate groin access (n=1). Transapical Aortic Valve Implantation with the Corevalve Revalving System was evaluated on Successful implantation (feasibility). Transapical aortic valve implantation with the Corevalve Revalving System was successfully performed, demonstrating feasibility for high-risk patients with inadequate groin access.